It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2017

Aptuit Selected as a Winner of Life Science Leader Global Award for Contract Drug Manufacturer in Multiple Categories
Nerina Coppini, 13 March 2017

Greenwich, CT – March 13, 2017 - Aptuit, LLC today announced that the company has been selected as a winner of four Contract Manufacturer Organization (CMO) Leadership Awards by Life Science Leader magazine. Aptuit was selected from a survey of pharma and biopharma companies who had outsourced projects within the past 18 months. Customers judge...

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens
Nerina Coppini, 7 March 2017

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard